1 year return (CAGR)
-59.50%
Medicenna Therapeutics Corp Exchange (TO, CAD)
MDNA.TO
0.41
-0.01 (-1.22%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
2.15%
5 year return (CAGR)
-33.61%
10 year return (CAGR)
-
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
37.38M
Price/Sales
-
Ent value
38.27M
Price/Book
22.34
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
-7.28%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 0.40 |
| Daily high | 0.41 |
| Daily low | 0.40 |
| Daily Volume | 2K |
| All-time high | 7.00 |
| 1y analyst estimate | 3.20 |
| Beta | 1.96 |
| EPS (TTM) | -0.21 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| MDNA.TO | S&P500 | |
| Current price drop from All-time high | -94.21% | -1.29% |
| Highest price drop | -96.86% | -56.47% |
| Date of highest drop | 1 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -62.74% | -10.68% |
| Avg time to new high | 77 days | 12 days |
| Max time to new high | 1586 days | 1805 days |
News
TORONTO and HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superki...
September 24, 2026
MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer a...
June 26, 2026
New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio n...
June 11, 2026
Medicenna Therapeutics (MDNA.TO) said Wednesday that its lead compound MDNA11 was featured in a post
June 3, 2026
NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses Up to 80 patients with lo...
June 3, 2026
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: M...
May 28, 2026
Base shelf prospectus is accessible on SEDAR+NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna ...
May 22, 2026
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Compa...
May 13, 2026
NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/...
May 12, 2026
Medicenna Therapeutics (MDNA.TO) reported Tuesday that the first patient has been dosed in a Phase 1
May 12, 2026